AAIC 2022 | Significance of targeting modifiable risk factors in Alzheimer’s patient care

James Galvin, MD, MPH, University of Miami Miller School of Medicine, Miami, FL, discusses the developments in targeting modifiable risk factors in Alzheimer’s disease (AD). There has been an increasing interest in how lifestyle factors can influence the risk of disease and disease progression, and this has resulted in an emphasis on multimodal therapeutic approaches in AD. While advances in drug development are rapidly occurring, it is important to consider how pharmacological and holistic care can be utilized collectively in treating AD and related disorders. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.